COVID-19: long-term health impacts
Open Access
- 15 December 2021
- journal article
- Published by Consilium Medicum in Consilium Medicum
- Vol. 23 (12), 993-999
- https://doi.org/10.26442/20751753.2021.12.201347
Abstract
Several studies have recently been conducted showing persistent COVID-19 symptoms in patients recovering after the acute phase of the disease. Energy imbalance plays a leading role in the pathogenesis of post-COVID syndrome. The choice of a metabolic cytoprotection drug with anti-asthenic activity will be decisive for the further tactics of managing the patient not only in the hospital, but also during the entire further period of recovery after the infection.Keywords
This publication has 40 references indexed in Scilit:
- Persistent Symptoms in Patients After Acute COVID-19JAMA, 2020
- Neurobiology of COVID-19Journal of Alzheimer's Disease, 2020
- Comment to the article “Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study”European Archives of Oto-Rhino-Laryngology, 2020
- 18FDG PET/CT Scan Reveals Hypoactive Orbitofrontal Cortex in Anosmia of COVID-19Academic Radiology, 2020
- Neurological involvement in SARS-CoV-2 infection: A clinical systematic reviewBrain, Behavior, & Immunity - Health, 2020
- Brainstem Dysfunction in SARS-COV2 Infection Can Be a Potential Cause of Respiratory DistressPreprints.org, 2020
- Meldonium as a supernosological drugConsilium Medicum, 2020
- The international collaborative on fatigue following infection (COFFI)Fatigue: Biomedicine, Health & Behavior, 2018
- The hidden burden of influenza: A review of the extra‐pulmonary complications of influenza infectionInfluenza and Other Respiratory Viruses, 2017
- Mental fatigue impairs physical performance in humansJournal of Applied Physiology, 2009